Article

Circulating Cardiac Troponin-I Autoantibodies in Human Plasma and Serum

Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, Illinois 60064-6016, USA.
Annals of the New York Academy of Sciences (Impact Factor: 4.31). 09/2009; 1173(1):67-74. DOI: 10.1111/j.1749-6632.2009.04617.x
Source: PubMed

ABSTRACT We identified IgG reactive with human cardiac troponin-I (cTnI) in plasma and serum samples (N = 1930) from normal blood donors, and in sample cohorts characterized on the basis of clinical biomarkers associated with cardiac, infectious, and autoimmune diseases. cTnI and brain natriuretic peptide were the biomarkers chosen to reflect myocyte damage or left ventricular dysfunction, respectively. The infectious disease cohorts were serologically positive for antibodies to hepatitis B (natural infection), hepatitis C virus, and Chagas (i.e., T.cruzi). The autoimmune cohorts were represented by samples from diagnosed systemic lupus erythematosus (biomarker: dsDNA) and rheumatoid arthritis (biomarker: rheumatoid factor) subjects. The prevalence of IgG autoantibodies reactive with cTnI was high in the normal donor cohort (95/750, 12.7%). The prevalence in the other sample cohorts was not significantly different from that in the normal blood donors, with the exception of a slight increase in the rheumatoid factor cohort (28/137, 20.4%). The presence of anti-cTnI IgG in highly reactive samples was confirmed by inhibition with the antigen and further by screening with a library of peptides derived from the human cTnI amino acid sequence. Our data suggest that these autoantibodies are polyspecific, encompassing epitopes across the entire cTnI sequence, including the cardiac-specific amino terminal region.

0 Followers
 · 
83 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’évolution rapide des méthodes de dosage des troponines cardiaques (cTn) vers une meilleure sensibilité analytique (cTn de haute sensibilité ou cTn HS) s’accompagne de nombreuses données de la littérature, mais encore incomplètes. En l’absence de standardisation des cTn et de données consensuelles sur l’utilisation et l’interprétation des résultats, les auteurs de cette revue proposent, à partir d’une revue de la littérature, et de façon multidisciplinaire, des éléments de réponses aux questions fréquemment posées. En conclusion, le bon usage des cTn HS repose sur la connaissance : 1) des caractéristiques propres de la méthode utilisée, en particulier de la précision obtenue au 99e percentile d’une population de référence ; 2) des facteurs de variation de la valeur du 99e percentile ; 3) de la forte individualité des dosages de cTn HS, pour lesquels la notion de cinétique individuelle est plus informative que la simple référence à des valeurs usuelles. La significativité des variations entre deux dosages n’est pas encore documentée pour toutes les méthodes HS. La collaboration entre cliniciens et biologistes est nécessaire à une meilleure utilisation des troponines au quotidien. Abstract The recent evolution of cardiac troponin assays (cTn) for acquisition of a better analytical sensitivity (high-sensitivity cTn, or cTn HS) is widely described in the literature; however, actual data remain incomplete. Considering the absence of cTn assays standardisation and of consensual data for using and interpreting cTn results, the authors propose multidisciplinary responses to frequently asked questions. Proper use of cTn HS relies upon knowledge of 1) the assay characteristics, and mainly the observed precision at the 99th percentile value; 2) the variation factors of the 99th percentile value; and 3) the high individuality of cTn HS tests, for which the notion of kinetics is more informative than the single reference to ‘normal’ values. Significant variation between 2 measurements, is not already documented for every HS assay. A strong partnership between clinicians and biologists is needed for a better understanding and use of cTn HS in routine.
    07/2014; 4(4):221-241. DOI:10.1007/s13341-014-0423-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimThe role that plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponins T (cTnT) and I (cTnI) play in supplementing imaging to screen for cardiac late effects remains controversial and the impact of high-sensitivity cTnT and troponin-specific autoantibodies (cTnAAbs) remains unexplored. We studied the role of cardiac biomarkers as indicators of the late effects of anthracyclines among childhood cancer survivors.Methods We measured NT-proBNP, cTnT, high-sensitivity cTnT, cTnI and cTnAAbs in 76 childhood cancer survivors at a median of 9 years after primary diagnosis. The survivors underwent conventional and real-time three-dimensional echocardiography and 62 underwent cardiac magnetic resonance imaging (MRI).ResultsOf the survivors, four (5.3%) without risk factors for cardiotoxicity were cTnAAb-positive with an impaired cardiac function in MRI. Another four (5.3%) had an abnormal NT-proBNP level associated with an abnormal cardiac function and risk factors for cardiotoxicity. None showed measurable cardiac troponins, determined by the three different methods, with even the high-sensitivity cTnT-levels remaining normal.Conclusion Elevated plasma NT-proBNP or cTnAAbs indicated that childhood cancer survivors benefitted from being evaluated with modern imaging, despite normal function in conventional echocardiography. However, troponins did not seem to provide additional information on the late cardiotoxicity of anthracyclines.
    Acta paediatrica (Oslo, Norway: 1992). Supplement 11/2014; 104(3). DOI:10.1111/apa.12862
  • 02/2015; DOI:10.1016/j.repc.2015.01.001